Literature DB >> 6184572

An oral calcium antagonist for treatment of hypertensive emergencies.

D Conen, O Bertel, U C Dubach.   

Abstract

The efficacy and safety of 20 mg of nifedipine as a single oral dose have been studied with respect to the use of the drug as an alternative treatment of hypertensive emergencies. The study population consisted of nine male and nine female patients, 47 to 80 years old. The mean systolic blood pressure decreased from 220 +/- 22 to 150 +/- 21 mm Hg and the mean diastolic blood pressure from 122 +/- 11 to 86 +/- 10 mm Hg (p less than 0.001) within 20-30 min. The decrease of blood pressure was paralleled by a small but significant increase (p less than 0.01) in heart rate from 74 +/- 9 to 85 +/- 10 beats/min. The fall of blood pressure was directly related to pretreatment values. Oral nifedipine can be recommended as a first-line drug to lower blood pressure in hypertensive emergencies.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6184572

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  4 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Hypertensive emergencies and urgencies: definition, recognition, and management.

Authors:  J B Reuler; G J Magarian
Journal:  J Gen Intern Med       Date:  1988 Jan-Feb       Impact factor: 5.128

3.  The influence of alpha 1-adrenergic blockade on the acute antihypertensive effect of nifedipine.

Authors:  H E Sluiter; F T Huysmans; T A Thien; R A Koene
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 4.  Treatment of severe hypertension and hypertensive crises with nifedipine.

Authors:  M C Houston
Journal:  West J Med       Date:  1987-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.